Serum Apolipoprotein A-I Predicts Response of Rectal Cancer to Neoadjuvant Chemoradiotherapy

References

• Petrelli F, Trevisan F, Cabiddu M, et al. Total neoadjuvant therapy in rectal cancer: a systematic review and meta-analysis of treatment outcomes. Ann Surg. 2020;271(3):440–448. doi:10.1097/SLA.000000000000347131318794
   PubMed Web of Science ®Google Scholar
• Erlandsson J, Lörinc E, Ahlberg M, et al. Tumour regression after radiotherapy for rectal cancer - results from the randomised stockholm III trial. Radiother Oncol. 2019;135:178–186. doi:10.1016/j.radonc.2019.03.01631015165
   PubMed Web of Science ®Google Scholar
• Fokas E, Ströbel P, Fietkau R, et al; German Rectal Cancer Study Group. Tumor regression grading after preoperative chemoradiotherapy as a prognostic factor and individual-level surrogate for disease-free survival in rectal cancer. J Natl Cancer Inst. 2017;109(12):djx095. doi:10.1093/jnci/djx095
   Google Scholar
• Rijkmans EC, Marijnen CAM, van Triest B, et al. Predictive factors for response and toxicity after brachytherapy for rectal cancer; results from the HERBERT study. Radiother Oncol. 2019;133:176–182. doi:10.1016/j.radonc.2019.01.03430935576
   PubMed Web of Science ®Google Scholar
• Nie K, Shi L, Chen Q, et al. Rectal cancer: assessment of neoadjuvant chemoradiation outcome based on radiomics of multiparametric MRI. Clin Cancer Res. 2016;22(21):5256–5264. doi:10.1158/1078-0432.CCR-15-299727185368
   PubMed Web of Science ®Google Scholar
• Cho E, Park IJ, Yeom SS, et al. A multigene model for predicting tumor responsiveness after preoperative chemoradiotherapy for rectal cancer. Int J Radiat Oncol Biol Phys. 2019;105(4):834–842. doi:10.1016/j.ijrobp.2019.07.05831419511
   PubMed Web of Science ®Google Scholar
• Akiyoshi T, Tanaka N, Kiyotani K, et al. Immunogenomic profiles associated with response to neoadjuvant chemoradiotherapy in patients with rectal cancer. Br J Surg. 2019;106(10):1381–1392. doi:10.1002/bjs.1117931197828
   PubMed Web of Science ®Google Scholar
• Yang KL, Yang SH, Liang WY, et al. Carcinoembryonic antigen (CEA) level, CEA ratio, and treatment outcome of rectal cancer patients receiving pre-operative chemoradiation and surgery. Radiat Oncol. 2013;8:43. doi:10.1186/1748-717X-8-4323452434
   PubMed Web of Science ®Google Scholar
• Hu H, Huang J, Lan P, et al. CEA clearance pattern as a predictor of tumor response to neoadjuvant treatment in rectal cancer: a post-hoc analysis of FOWARC trial. BMC Cancer. 2018;18(1):1145. doi:10.1186/s12885-018-4997-y30458734
   PubMed Web of Science ®Google Scholar
• Tan Y, Fu D, Li D, et al. Predictors and risk factors of pathologic complete response following neoadjuvant chemoradiotherapy for rectal cancer: a population-based analysis. Front Oncol. 2019;9:497. doi:10.3389/fonc.2019.0049731263674
   PubMed Web of Science ®Google Scholar
• Song J, Huang X, Chen Z, et al. Predictive value of carcinoembryonic antigen and carbohydrate antigen 19-9 related to downstaging to stage 0-I after neoadjuvant chemoradiotherapy in locally advanced rectal cancer. Cancer Manag Res. 2018;10:3101–3108. doi:10.2147/CMAR.S16641730214303
   PubMed Web of Science ®Google Scholar
• Lee JH, Song C, Kang SB, Lee HS, Lee KW, Kim JS. Predicting pathological complete regression with haematological markers during neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Anticancer Res. 2018;38(12):6905–6910. doi:10.21873/anticanres.1306730504408
   PubMed Web of Science ®Google Scholar
• Parhofer KG. New approaches to address dyslipidemia. Curr Opin Lipidol. 2017;28(6):452–457. doi:10.1097/MOL.000000000000045628902717
   PubMed Web of Science ®Google Scholar
• Agnoli C, Grioni S, Sieri S, et al. Colorectal cancer risk and dyslipidemia: a case-cohort study nested in an Italian multicentre cohort. Cancer Epidemiol. 2014;38(2):144–151. doi:10.1016/j.canep.2014.02.00224636241
   PubMed Web of Science ®Google Scholar
• Quan Q, Huang Y, Chen Q, et al. Impact of serum apolipoprotein A-I on prognosis and bevacizumab efficacy in patients with metastatic colorectal cancer: a propensity score-matched analysis. Transl Oncol. 2017;10(2):288–294. doi:10.1016/j.tranon.2017.01.00628292509
   PubMed Web of Science ®Google Scholar
• Del Boccio P, Perrotti F, Rossi C, et al. Serum lipidomic study reveals potential early biomarkers for predicting response to chemoradiation therapy in advanced rectal cancer: a pilot study. Adv Radiat Oncol. 2017;2(2):118–124. doi:10.1016/j.adro.2016.12.00528740922
   PubMedGoogle Scholar
• Hammarström K, Imam I, Mezheyeuski A, et al. Evaluation of associations between routinely collected staging information and the response to (chemo)radiotherapy in rectal cancer. Cancers. 2020;13(1):16. doi:10.3390/cancers13010016
   PubMed Web of Science ®Google Scholar
• Lee-Rueckert M, Escola-Gil JC, Kovanen PT. HDL functionality in reverse cholesterol transport–challenges in translating data emerging from mouse models to human disease. Biochim Biophys Acta. 2016;1861(7):566–583. doi:10.1016/j.bbalip.2016.03.00426968096
   PubMed Web of Science ®Google Scholar
• Zamanian-Daryoush M, DiDonato JA. Apolipoprotein A-I and cancer. Front Pharmacol. 2015;6:265. doi:10.3389/fphar.2015.0026526617517
   PubMed Web of Science ®Google Scholar
• Ben Hassen C, Gutierrez-Pajares JL, Guimaraes C, et al. Apolipoprotein-mediated regulation of lipid metabolism induces distinctive effects in different types of breast cancer cells. Breast Cancer Res. 2020;22(1):38. doi:10.1186/s13058-020-01276-932321558
   PubMed Web of Science ®Google Scholar
• Cheng T, Dai X, Zhou DL, Lv Y, Miao LY. Correlation of apolipoprotein A-I kinetics with survival and response to first-line platinum-based chemotherapy in advanced non-small cell lung cancer. Med Oncol. 2015;32(1):407. doi:10.1007/s12032-014-0407-825465061
   PubMed Web of Science ®Google Scholar
• Guo S, He X, Chen Q, et al. The effect of preoperative apolipoprotein A-I on the prognosis of surgical renal cell carcinoma: a Retrospective Large Sample Study. Medicine. 2016;95(12):e3147. doi:10.1097/MD.000000000000314727015197
   PubMed Web of Science ®Google Scholar
• Wang XP, Li XH, Zhang L, et al. High level of serum apolipoprotein A-I is a favorable prognostic factor for overall survival in esophageal squamous cell carcinoma. BMC Cancer. 2016;16:516. doi:10.1186/s12885-016-2502-z27444612
   PubMed Web of Science ®Google Scholar
• Chang H, Wei JW, Chen K, et al. Apolipoprotein A-I is a prognosticator of nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy. J Cancer. 2018;9(4):702–710. doi:10.7150/jca.2283629556328
   PubMed Web of Science ®Google Scholar
• Ye J, Luo QY, Wang XP, et al. Serum apolipoprotein A-I combined with c-reactive protein serves as a novel prognostic stratification system for colorectal cancer. Cancer Manag Res. 2019;11:9265–9276. doi:10.2147/CMAR.S21559931802946
   PubMed Web of Science ®Google Scholar
• Yang DD, Chen ZH, Wang DS, et al. Prognostic value of the serum apolipoprotein B to apolipoprotein A-I ratio in metastatic colorectal cancer patients. J Cancer. 2020;11(5):1063–1074. doi:10.7150/jca.3565931956353
   PubMed Web of Science ®Google Scholar
• Sun Y, Chi P, Lin H, et al. A nomogram predicting pathological complete response to neoadjuvant chemoradiotherapy for locally advanced rectal cancer: implications for organ preservation strategies. Oncotarget. 2017;8(40):67732–67743. doi:10.18632/oncotarget.1882128978067
   PubMedGoogle Scholar
• Engel RM, Oliva K, Koulis C, Yap R, McMurrick PJ. Predictive factors of complete pathological response in patients with locally advanced rectal cancer. Int J Colorectal Dis. 2020;35(9):1759–1767. doi:10.1007/s00384-020-03633-832474708
   PubMed Web of Science ®Google Scholar
• Kakuda H, Matoba M, Nakatoh H, Nagao S, Takekoshi N. Effects of change in high-density lipoprotein cholesterol by statin switching on glucose metabolism and renal function in hypercholesterolemia. J Clin Lipidol. 2015;9(5):709–715. doi:10.1016/j.jacl.2015.07.00726350819
   PubMed Web of Science ®Google Scholar
• Pang J, Chan DC, Hamilton SJ, Tenneti VS, Watts GF, Barrett PH. Effect of niacin on high-density lipoprotein apolipoprotein A-I kinetics in statin-treated patients with type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol. 2014;34(2):427–432. doi:10.1161/ATVBAHA.113.30201924285582
   PubMed Web of Science ®Google Scholar
• Gash KJ, Chambers AC, Cotton DE, et al. Potentiating the effects of radiotherapy in rectal cancer: the role of aspirin, statins and metformin as adjuncts to therapy. Br J Cancer. 2017;117(2):210–219. doi:10.1038/bjc.2017.17528641310
   PubMed Web of Science ®Google Scholar
• Karagkounis G, DeVecchio J, Ferrandon S, Williams AC, Thomas MG. Simvastatin enhances radiation sensitivity of colorectal cancer cells. Surg Endosc. 2018;32(3):1533–1539. doi:10.1007/s00464-017-5841-128916945
   PubMed Web of Science ®Google Scholar
• Delk SC, Chattopadhyay A, Escola-Gil JC, Fogelman AM, Reddy ST. Apolipoprotein mimetics in cancer. Semin Cancer Biol. 2020. doi:10.1016/j.semcancer.2020.11.002
   PubMed Web of Science ®Google Scholar